Compare TRIB & ICCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TRIB | ICCM |
|---|---|---|
| Founded | 1992 | 2006 |
| Country | Ireland | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.4M | 8.3M |
| IPO Year | 1996 | 2013 |
| Metric | TRIB | ICCM |
|---|---|---|
| Price | $6.79 | $0.98 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $22.67 |
| AVG Volume (30 Days) | 13.2K | ★ 167.9K |
| Earning Date | 06-16-2026 | 11-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $35.89 | $27.11 |
| Revenue Next Year | N/A | $104.97 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.28 | $0.13 |
| 52 Week High | $14.17 | $9.54 |
| Indicator | TRIB | ICCM |
|---|---|---|
| Relative Strength Index (RSI) | 44.95 | 22.39 |
| Support Level | $6.85 | $0.96 |
| Resistance Level | $7.45 | $2.50 |
| Average True Range (ATR) | 0.88 | 0.10 |
| MACD | 0.04 | 0.03 |
| Stochastic Oscillator | 30.19 | 41.39 |
Trinity Biotech PLC is in the business of developing, manufacturing, and marketing clinical diagnostic products for clinical laboratory and point-of-care sections of the diagnostic market. Its products are used to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company also provides raw materials to the life sciences and research industries globally. It markets products under the brand names Recombigen, Unigold, MarBlot, Mardx, Immublot, and others. Geographically, it has three segments, namely the Americas, Asia/Africa, and Europe, from which it derives a majority of its revenue from the Americas segment.
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.